UBX
Price:
$1.26
Market Cap:
$21.23M
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed ...[Read more]
Industry
Biotechnology
IPO Date
2018-05-03
Stock Exchange
NASDAQ
Ticker
UBX
According to Unity Biotechnology, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 35.30M. This represents a change of -16.27% compared to the average of 42.16M of the last 4 quarters.
The mean historical Enterprise Value of Unity Biotechnology, Inc. over the last ten years is 155.47M. The current 35.30M Enterprise Value has changed 2.17% with respect to the historical average. Over the past ten years (40 quarters), UBX's Enterprise Value was at its highest in in the December 2017 quarter at 690.40M. The Enterprise Value was at its lowest in in the June 2017 quarter at 0.
Average
155.47M
Median
80.39M
Minimum
-32054289.00
Maximum
444.39M
Discovering the peaks and valleys of Unity Biotechnology, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 786.38%
Maximum Annual Enterprise Value = 444.39M
Minimum Annual Increase = -256.41%
Minimum Annual Enterprise Value = -32054289.00
Year | Enterprise Value | Change |
---|---|---|
2023 | 35.70M | -41.13% |
2022 | 60.64M | -39.45% |
2021 | 100.14M | -67.45% |
2020 | 307.70M | 11.04% |
2019 | 277.11M | -37.64% |
2018 | 444.39M | 786.38% |
2017 | 50.14M | -256.41% |
The current Enterprise Value of Unity Biotechnology, Inc. (UBX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
65.49M
5-year avg
156.26M
10-year avg
155.47M
Unity Biotechnology, Inc.’s Enterprise Value is less than Exscientia plc (372.98M), less than Recursion Pharmaceuticals, Inc. (1.50B), less than Atea Pharmaceuticals, Inc. (41.44M), less than Icosavax, Inc. (713.87M), greater than HOOKIPA Pharma Inc. (-26926933.00), less than Acumen Pharmaceuticals, Inc. (137.49M), less than Heron Therapeutics, Inc. (430.30M), greater than Homology Medicines, Inc. (-103303255.00), less than Avidity Biosciences, Inc. (4.68B), less than Beam Therapeutics Inc. (1.88B), less than Intellia Therapeutics, Inc. (1.51B), less than Editas Medicine, Inc. (211.79M), less than Verve Therapeutics, Inc. (442.96M), less than Prime Medicine, Inc. (461.31M), greater than Windtree Therapeutics, Inc. (8.18M), greater than Dermata Therapeutics, Inc. (-3107527.00), greater than Ensysce Biosciences, Inc. (8.03M), greater than Panbela Therapeutics, Inc. (5.93M), greater than Baudax Bio, Inc. (15.86M), greater than Neoleukin Therapeutics, Inc. (-6333315.00), less than Nuvation Bio Inc. (1.02B), less than Ovid Therapeutics Inc. (70.41M), greater than NextCure, Inc. (21.96M), greater than Connect Biopharma Holdings Limited (-43544162.00),
Company | Enterprise Value | Market cap |
---|---|---|
372.98M | $636.36M | |
1.50B | $1.89B | |
41.44M | $282.81M | |
713.87M | $769.04M | |
-26926933.00 | $45.33M | |
137.49M | $177.24M | |
430.30M | $269.97M | |
-103303255.00 | $3.02M | |
4.68B | $5.25B | |
1.88B | $2.01B | |
1.51B | $1.54B | |
211.79M | $237.53M | |
442.96M | $511.98M | |
461.31M | $475.32M | |
8.18M | $6.12M | |
-3107527.00 | $1.84M | |
8.03M | $8.63M | |
5.93M | $1.80M | |
15.86M | $8.13M | |
-6333315.00 | $8.20M | |
1.02B | $764.36M | |
70.41M | $83.75M | |
21.96M | $36.65M | |
-43544162.00 | $66.30M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Unity Biotechnology, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Unity Biotechnology, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Unity Biotechnology, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Unity Biotechnology, Inc. (UBX)?
What is the 3-year average Enterprise Value for Unity Biotechnology, Inc. (UBX)?
What is the 5-year average Enterprise Value for Unity Biotechnology, Inc. (UBX)?
How does the current Enterprise Value for Unity Biotechnology, Inc. (UBX) compare to its historical average?